what's new in her2? evaluating the evidence in non-small cell lung cancer
Published 1 month ago • 5 plays • Length 15:34Download video MP4
Download video MP3
Similar videos
-
57:49
understanding her2 alterations in advanced non-squamous nsclc
-
1:13
challenges to targeting her2 in lung cancer
-
1:45
strategies to target her2 in lung cancer
-
7:13
what are the options: lung cancer & non-small cell lung cancer (nsclc)
-
5:49
top 5 developments in lung cancer in 2021
-
1:31:34
tailoring targeted therapy: new directions for managing patients across the spectrum of nsclc
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
1:12
dr. yorio on t-dm1 in her2-mutant lung cancer treatment
-
5:53
nccn guidelines pave way for improving lung cancer survival
-
58:30
the potential of her2-, her3-, and trop2-targeted therapies to address unmet needs in advanced nsclc
-
1:41
what is a her2 mutation in lung cancer?
-
4:24
zenith20-4: efficacy & safety of poziotinib in treatment-naïve nsclc with her2 exon 20 mutations
-
5:50
ctdna shows promise for assessing lung cancer treatment response
-
6:46
locally advanced lung cancer: no longer 'one size fits all'
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
4:12
the future of small cell lung cancer care
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
7:44
next-generation targeted therapies in non-small cell lung cancer
-
12:33
introduction: checkpoint inhibition in non-small cell lung cancer